Open an account

Syros Pharmaceuticals

SYRS · OTC

$0.0004+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0004

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is actively engaged in the voluntary delisting process. The firm was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees
68
Headquarters
Cambridge, Massachusetts
Listed
Jun 30, 2016
Sector
Health Care
Industry
Biotechnology
Website
syros.com

SYRS key statistics

Market cap
10.73K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.78K
Volume
30.55K
Open price
$0.0004
High today
$0.0004
Low today
$0.0004
52 Week high
$0.02
52 Week low
$0.00

Syros Pharmaceuticals (SYRS) at a glance

Syros Pharmaceuticals (SYRS) last traded at $0.0004, with a market cap of 10.73K and a price-to-earnings ratio of 0.00.

Volume so far is 30.55K shares, above the average of 9.78K shares a day.

Over the past year Syros Pharmaceuticals has ranged from $0.00 to $0.02, and now sits 2% of the way up that range.

Syros Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY24 it reported -$0.16 per share against an estimate of -$0.7344.

SYRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 60.6% on average.

  1. Q4 FY22: reported -$0.17 per share against an estimate of -$1.38
  2. Q1 FY23: reported -$0.85 per share against an estimate of -$1.11
  3. Q2 FY23: reported -$1.30 per share against an estimate of -$1.15
  4. Q3 FY23: reported -$1.43 per share against an estimate of -$1.16
  5. Q4 FY23: reported -$2.18 per share against an estimate of -$1.17
  6. Q1 FY24: reported -$0.10 per share against an estimate of -$0.8862
  7. Q2 FY24: reported -$0.59 per share against an estimate of -$0.7832
  8. Q3 FY24: reported -$0.16 per share against an estimate of -$0.7344

SYRS news

  • Press releasePRNewswire

    Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    US Stocks Mixed; Kohl's Shares Plunge After Q4 Results

  • Rishabh Mishra

    US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert

  • Press releaseBusiness Wire

    Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Syros Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.